株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の肛門癌および大腸癌市場の分析と予測

Global Anal and Colorectal Cancer Market Research and Forecast 2018-2023

発行 Orion Market Research Pvt Ltd 商品コード 611085
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.43円で換算しております。
Back to Top
世界の肛門癌および大腸癌市場の分析と予測 Global Anal and Colorectal Cancer Market Research and Forecast 2018-2023
出版日: 2018年02月01日 ページ情報: 英文
概要

当レポートでは、肛門癌および大腸癌の世界市場について調査し、市場の概要、診断法・治療法・エンドユーザー・地域別の市場動向、市場規模の推移と予測、市場促進要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 レポート概要

  • 調査手法
  • 市場区分
    • セグメント別
    • 地域別
    • ステークホルダー別
    • 例外事項

第2章 市場概要と考察

  • 市場の定義
  • アナリストによる考察と市場動向
    • 主な所見
    • 提言
    • 総論
  • 規制動向
    • 米国
    • 欧州
    • 中国
    • インド
  • 特許分析

第3章 市場の決定要因

  • 市場促進要因
  • 市場阻害要因
  • 市場機会

第4章 市場区分

  • 診断法別
    • 大腸癌診断
    • 肛門癌診断
  • 治療法別
    • 手術
    • 放射線治療
    • 化学療法
    • 分子標的治療
    • 免疫療法
  • エンドユーザー別
    • 病院
    • 外来外科センター
    • 癌研究センター

第5章 競合環境

  • 戦略分析
  • 主要企業の分析

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • その他
  • その他の地域

第7章 企業プロファイル

  • ABBOTT DIAGNOSTICS
  • ADVAXIS INC
  • ALERE
  • AMGEN INC
  • ATARA BIOTHERAPEUTICS INC
  • BAYER AG
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BECKMAN COULTER
  • BEIGENE LTD
  • BOEHRINGER INGELHEIM
  • CLINICAL GENOMICS
  • EDP BIOTECH
  • ELI LILLY AND COMPANY
  • EPIGENOMICS
  • EXACT SCIENCES
  • GENOMICTREE
  • IMMUNOVACCINE INC
  • ISA PHARMACEUTICALS BV
  • MERCK & CO INC
  • METABIOMICS
  • 小野薬品工業
  • ORYX GMBH & CO KG
  • PDS BIOTECHNOLOGY CORP
  • QUEST DIAGNOSTICS
  • RANDOX LABORATORIES
  • ROCHE LTD.
  • SIEMENS HEALTHCARE
  • SUN PHARMA ADVANCED RESEARCH COMPANY LTD
  • 大鵬薬品工業
  • TAIWAN LIPOSOME COMPANY LTD
  • VOLITION RX
目次
Product Code: OMR2017226

Colorectal cancer is a malignant tumor that starts in the cells of the colon or the rectum while it takes place in anus in case of anal cancer. Rising prevalence of anal and colorectal cancer due to poor lifestyles such as obesity and tobacco consumption has been the major factor driving the market growth. Colorectal cancer is the third most common malignancy and fourth leading cause of cancer-related mortalities globally. It accounts for around 1.4 million incidences and more than 700,000 fatalities across the globe. As per American Cancer Society, around 8,580 new cases of anal cancer are expected in 2018. Additionally, increasing geriatric population and rising anal and colorectal cancer associated with them is another factor driving the market growth. Moreover, high prevalence of smokers and alcohol consumers which are most prone to this cancer has been boosting the market growth. According to WHO, in 2015, more than 1.1 billion people accounted for tobacco smoking and around 2 billion people consumed alcoholic drinks globally. These people have more risk of developing anal cancer and such high prevalence reflects the demand of treatment among population in major countries.

High cost of anal and colorectal cancer treatment along with low awareness towards this cancer act as major restraints for the market growth. However, ongoing improvements in the healthcare expenditure and rising demand of anal and colorectal cancer treatment are expected to drive the market in the developing countries. Additionally, rising demand of minimally invasive surgeries and technological advancement for the treatment of the cancer is expected to boost the market in future.

On the basis of the geography, anal and colorectal cancer market is segmented into North America, Asia Pacific, Europe and Rest of the World. North America has been predicted to dominate the global anal and colorectal cancer market due to well established health infrastructure and high prevalence of this cancer towards people. Additionally, APAC will be the fastest growing region during the forecasted period due to rising geriatric population and increasing incidence and prevalence rate of anal and colorectal cancer.

The key players in the anal and colorectal cancer market Include Abbott Diagnostics, Alere, Taiwan Liposome Company Ltd., Merck & Co., Quest Diagnostics, Roche Ltd., and Taiho Pharmaceutical. FDA Clearance has been recorded as the major breakthrough in the anal and colorectal cancer market. For instance, Roche got the FDA clearance of CE-marked Ventana MMR IHC Panel in November, 2017 for clinicians with a broad portfolio of immunohisto chemistry (IHC) tests for colorectal cancers patients.

Market Segmentation

Global anal and colorectal cancer market has been segmented on the basis of diagnosis type, by treatment type and by end users. On the basis of diagnosis type, the market has been segmented into colorectal diagnosis and anal cancer diagnosis. Additionally, the market has been segmented on the basis of treatment type into surgery, chemotherapy, radiation therapy, targeted therapy and immuno therapy. Moreover, on the basis of end users, the market is segmented into hospitals, ambulatory surgery centers and cancer research centers. Global Anal and colorectal cancer market is bifurcated as follows:

  • Global Anal and colorectal Cancer Market Research and Analysis, By Diagnosis Type
  • Global Anal and colorectal Cancer Market Research and Analysis, By Treatment Type
  • Global Anal and colorectal Cancer Market Research and Analysis, By End-Users

The Report covers

  • Comprehensive research methodology of Global Anal and colorectal Cancer Market.
  • This report also includes detailed and extensive market overview with current market recommendations & key analysts insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Global Anal and colorectal Cancer Market.
  • Insights about market determinants which are stimulating the Global Anal and colorectal Cancer Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

  • 1. REPORT SUMMARY
  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
  • 1.2.1. BY SEGMENTS
  • 1.2.2. BY GEOGRAPHY
  • 1.2.3. BY STAKEHOLDERS
  • 2. MARKET OVERVIEW AND INSIGHTS
  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
  • 2.2.1. KEY FINDINGS
  • 2.2.2. RECOMMENDATION
  • 2.2.3. CONCLUSION
  • 2.3. REGULATIONS
  • 2.3.1. UNITED STATES
  • 2.3.2. EUROPEAN UNION
  • 2.3.3. CHINA
  • 2.3.4. INDIA
  • 2.3.5. REST OF THE WORLD
  • 2.4. PATENT ANALYSIS
  • 3. MARKET DETERMINANT
  • 3.1. MOTIVATORS
  • 3.1.1. RISING NUMBER OF ANAL AND COLORECTAL CANCER
  • 3.1.2. GROWING OBESE POPULATION
  • 3.1.3. INCREASING PREVALENCE OF HUMAN PAPILLOMAVIRUS
  • 3.1.4. AVAILABILITY OF REIMBURSEMENT POLICIES
  • 3.2. RESTRAINTS
  • 3.2.1. HIGH COST OF TREATMENT
  • 3.2.2. LACK OF AWARENESS IN EMERGING ECONOMIES
  • 3.3. OPPORTUNITIES
  • 3.3.1. R&D AND TECHNOLOGICAL ADVANCEMENT
  • 3.3.2. EMERGING MARKET IN DEVELOPING COUNTRIES
  • 3.3.3. RISING DEMAND OF MINIMALLY INVASIVE SURGERIES
  • 4. MARKET SEGMENTATION
  • 4.1. ANAL AND COLORECTAL CANCER MARKET, BY DIAGNOSIS
  • 4.1.1. COLORECTAL CANCER DIAGNOSIS
  • 4.1.1.1. DIGITAL RECTAL EXAMINATION
  • 4.1.1.2. BIOPSY
  • 4.1.1.3. FECAL OCCULT BLOOD TEST
  • 4.1.1.4. FLEXIBLE SIGMOIDOSCOPY
  • 4.1.1.5. COLONOSCOPY
  • 4.1.2. ANAL CANCER DIAGNOSIS
  • 4.1.2.1. DIGITAL RECTAL EXAMINATION
  • 4.1.2.2. ANOSCOPY AND PROTOSCOPY
  • 4.1.2.3. BIOPSY
  • 4.1.2.4. IMAGING
  • 4.1.2.4.1. MRI
  • 4.1.2.4.2. CT-SCAN
  • 4.1.2.4.3. PET-CT SCAN
  • 4.2. ANAL AND COLORECTAL CANCER MARKET, BY TREATMENT
  • 4.2.1. SURGERY
  • 4.2.2. RADIATION THERAPY
  • 4.2.3. COLORECTAL CANCER CHEMOTHERAPY
  • 4.2.3.1. ADENOCARCINOMAS
  • 4.2.3.2. CARCINOID TUMORS
  • 4.2.3.3. LYMPHOMAS
  • 4.2.3.4. SARCOMAS
  • 4.2.3.5. GASTROINTESTINAL STROMAL TUMORS (GISTS)
  • 4.2.4. TARGETED THERAPY
  • 4.2.5. IMMUNOTHERAPHY
  • 4.3. ANAL AND COLORECTAL CANCER MARKET, BY END USERS
  • 4.3.1. HOSPITALS
  • 4.3.2. AMBULATORY SURGERY CENTRES
  • 4.3.3. CANCER RESEARCH CENTERS
  • 5. COMPETITIVE LANDSCAPE
  • 5.1. STRATEGY ANALYSIS
  • 5.2. KEY COMPANY ANALYSIS
  • 6. REGIONAL ANALYSIS
  • 6.1. NORTH AMERICA
  • 6.1.1. UNITED STATES
  • 6.1.2. CANADA
  • 6.2. EUROPE
  • 6.2.1. UNITED KINGDOM
  • 6.2.2. FRANCE
  • 6.2.3. GERMANY
  • 6.2.4. ITALY
  • 6.2.5. SPAIN
  • 6.2.6. REST OF EUROPE
  • 6.3. ASIA PACIFIC
  • 6.3.1. INDIA
  • 6.3.2. CHINA
  • 6.3.3. JAPAN
  • 6.4. REST OF THE WORLD
  • 7. COMPANY PROFILES
  • 7.1. ABBOTT DIAGNOSTICS
  • 7.2. ADVAXIS INC
  • 7.3. ALERE
  • 7.4. AMGEN INC
  • 7.5. ATARA BIOTHERAPEUTICS INC
  • 7.6. BAYER AG
  • 7.7. BAYER HEALTHCARE PHARMACEUTICALS
  • 7.8. BECKMAN COULTER
  • 7.9. BEIGENE LTD
  • 7.10. BOEHRINGER INGELHEIM
  • 7.11. CLINICAL GENOMICS
  • 7.12. EDP BIOTECH
  • 7.13. ELI LILLY AND COMPANY
  • 7.14. EPIGENOMICS
  • 7.15. EXACT SCIENCES
  • 7.16. GENOMICTREE
  • 7.17. IMMUNOVACCINE INC
  • 7.18. ISA PHARMACEUTICALS BV
  • 7.19. MERCK & CO INC
  • 7.20. METABIOMICS
  • 7.21. ONO PHARMACEUTICAL CO LTD
  • 7.22. ORYX GMBH & CO KG
  • 7.23. PDS BIOTECHNOLOGY CORP
  • 7.24. QUEST DIAGNOSTICS
  • 7.25. RANDOX LABORATORIES
  • 7.26. ROCHE LTD.
  • 7.27. SIEMENS HEALTHCARE
  • 7.28. SUN PHARMA ADVANCED RESEARCH COMPANY LTD
  • 7.29. TAIHO PHARMACEUTICAL
  • 7.30. TAIWAN LIPOSOME COMPANY LTD
  • 7.31. VOLITION RX

List of Tables

  • TABLE # 1 ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS TYPE 2017-2023($ MILLION)
  • TABLE # 2 COLORECTAL CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 3 COLORECTAL CANCER DIGITAL RECTAL EXAMINATION MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 4 COLORECTAL CANCER FECAL OCCULT BLOOD TEST MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 5 COLORECTAL CANCER FLEXIBLE SIGMOIDOSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 6 COLORECTAL CANCER COLONOSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 7 COLORECTAL CANCER BIOPSY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 8 ANAL CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 9 ANAL CANCER DIGITAL RECTAL EXAMINATION MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 10 ANAL CANCER ANOSCOPY AND PROTOSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 11 ANAL CANCER BIOPSY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 12 ANAL CANCER IMAGING MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 13 ANAL CANCER MRI MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 14 ANAL CANCER CT-SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 15 ANAL CANCER PET-CT SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 16 ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY TREATMENT TYPE, 2017-2023($ MILLION)
  • TABLE # 17 ANAL AND COLORECTAL CANCER SURGERY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 18 ANAL AND COLORECTAL CANCER RADIATION THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 19 COLORECTAL CANCER CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 20 COLORECTAL CANCER ADENOCARCINOMAS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 21 COLORECTAL CANCER CARCINOID TUMORS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 22 COLORECTAL CANCER LYMPHOMAS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 23 COLORECTAL CANCER SARCOMAS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 24 COLORECTAL CANCER GASTROINTESTINAL STROMAL TUMORS (GISTS) MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 25 ANAL AND COLORECTAL CANCER TARGETED THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 26 ANAL AND COLORECTAL CANCER IMMUNOTHERAPHY MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 27 ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY END USERS, 2017-2023($ MILLION)
  • TABLE # 28 ANAL AND COLORECTAL CANCER HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 29 ANAL AND COLORECTAL CANCER AMBULATORY SURGERY CENTRES MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 30 ANAL AND COLORECTAL CANCER RESEARCH CENTERS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
  • TABLE # 31 NORTH AMERICA ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS 2017-2023($MILLION)
  • TABLE # 32 NORTH AMERICA ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($MILLION)
  • TABLE # 33 NORTH AMERICA ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY END USER 2017-2023($MILLION)
  • TABLE # 34 NORTH AMERICA ANAL AND COLORECTAL CANCER DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023($MILLION)
  • TABLE # 35 EUROPE ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS 2017-2023($MILLION)
  • TABLE # 36 EUROPE ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($MILLION)
  • TABLE # 37 EUROPE ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY END USER 2017-2023($MILLION)
  • TABLE # 38 EUROPE ANAL AND COLORECTAL CANCER DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023($MILLION)
  • TABLE # 39 APAC ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS 2017-2023($MILLION)
  • TABLE # 40 APAC ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($MILLION)
  • TABLE # 41 APAC ANAL AND COLORECTAL CANCER MARKET RESEARCH AND ANALYSIS, BY END USER 2017-2023 ($MILLION)
  • TABLE # 42 APAC ANAL AND COLORECTAL CANCER DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023($MILLION)

List of Figures

  • FIGURE # 1 GLOBAL ANAL AND COLORECTAL CANCER MARKET SHARE BY DIAGNOSIS TYPE, 2017 VS 2023 (%)
  • FIGURE # 2 GLOBAL ANAL AND COLORECTAL CANCER MARKET SHARE BY TREATMENT TYPE, 2017 VS 2023 (%)
  • FIGURE # 3 GLOBAL ANAL AND COLORECTAL CANCER MARKET SHARE BY END-USERS, 2017 VS 2023 (%)
  • FIGURE # 4 GLOBAL ANAL AND COLORECTAL CANCER MARKET SHARE BY GEOGRAPHY, 2017 VS 2023 (%)
  • FIGURE # 5 NORTH AMERICAN ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 6 UNITED STATES ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 7 CANADA ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 8 EUROPEAN ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 9 UK ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 10 GERMANY ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 11 SPAIN ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 12 FRANCE ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 13 ITALY ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 14 ROE ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 15 ASIA PACIFIC ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 16 INDIA ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 17 CHINA ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 18 JAPAN ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 19 ROAPAC ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
  • FIGURE # 20 REST OF THE WORLD ANAL AND COLORECTAL CANCER MARKET SIZE, 2017-2023 ($ MILLION)
Back to Top